Management also diverges, High-dose glucocorticoids are the first-line treatment for ICI-related pneumonia, while EGFR-TKI-related ILD requires immediate discontinuation of the drug, with glucocorticoids used in combination if necessary (Ohmori et al., 2021; Skeoch et al., 2018). Here, EGFR is linked to susceptibility to pneumonia measurement.